Ask AI
HIV PrEP made practical module

CE / CME

PrEP Made Practical: HIV Prevention in Mental Health Care Settings

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Pharmacists: 0.75 contact hour (0.075 CEUs)

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: April 14, 2026

Expiration: April 13, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Angelino AF. Depression and adjustment disorder in patients with HIV disease. Top HIV Med. 2002;10:31-35.
  2. Rubin LH, Maki PM. HIV, depression, and cognitive impairment in the era of effective antiretroviral therapy. Curr HIV/AIDS Rep. 2019;16:82-95.
  3. Remien RH, Stirratt MJ, Nguyen N, et al. Mental health and HIV/AIDS: the need for an integrated response. AIDS. 2019;33:1411-1420.
  4. HIV.gov. Ending the HIV Epidemic in the U.S. hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies. Accessed April 7, 2026.
  5. Dukes C. Talking about S-E-X in healthcare settings: let's get clinical. Dela J Public Health. 2025;11:46-49.
  6. Sudler A, Cournos F, Arnold E, et al. The case for prescribing PrEP in community mental health settings. Lancet HIV. 2021;8:e237-e244.
  7. Sewell WC, Powell VE, Ball-Burack M, et al. Brief report: "I didn't really have a primary care provider until I got PrEP": patients' perspectives on HIV preexposure prophylaxis as a gateway to health care. J Acquir Immune Defic Syndr. 2021;88:31-35.
  8. Whitfield THF, Jones SS, Wachman M, et al. The impact of pre-exposure prophylaxis (PrEP) use on sexual anxiety, satisfaction, and esteem among gay and bisexual men. J Sex Res. 2019;56:1128-1135.
  9. Centers for Disease Control and Prevention. Clinical guidance for PrEP. cdc.gov/hivnexus/hcp/prep/index.html. Accessed April 7, 2026.
  10. Vail RM, Cantor A, Shah S, et al. Clinical guidelines program: PrEP to prevent HIV and promote sexual health. hivguidelines.org/guideline/hiv-prep/. Accessed April 7, 2026.
  11. Emtricitabine and disoproxil fumarate [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2024.
  12. Emtricitabine and tenofovir alafenamide [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2025.
  13. Cabotegravir [prescribing information]. Durham, NC: ViiV Healthcare; 2024.
  14. Lenacapavir [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2025.
  15. Unigwe IF, Goodin A, Lo-Ciganic WH, et al. Trajectories of adherence to oral pre-exposure prophylaxis and risks of HIV and sexually transmitted infections. Open Forum Infect Dis. 2024;11:ofae569.
  16. Rogers BG, Chan PA, Sutten-Coats C, et al. Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States. BMC Public Health. 2023;23:1643.
  17. John SA, Zapata JP, Dang M, et al. Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old. Sci Rep. 2023;13:5116.
  18. Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. JAMA. 2025;333:609-628.
  19. Landovitz RJ, Molina JM, Buchbinder SP; International Antiviral Society–USA (IAS-USA) Panel. Preexposure prophylaxis for HIV: updated recommendations from the 2024 International Antiviral Society-USA Panel. JAMA. 2025;334:638-639.
  20. Kelley CF, Acevedo-Quiñones M, Agwu AL, et al; PURPOSE 2 Study Team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392:1261-1276.
  21. Mngadi K, Phanuphak N, Hinojosa JC, et al. Preferences for twice-yearly injections vs daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men, and gender nonbinary people enrolled in PURPOSE 2. Presented at: International AIDS Society Conference on HIV Science 2025; July 13-17, 2025. Abstract OAC0502.
  22. Sullivan P, Brixner D, Lam JT, Hsiao A. Overcoming barriers to HIV prevention: population health considerations on optimizing PrEP access. Am J Manag Care. 2024;30(11 Suppl):S207-S215.
  23. Lavoie MC, Geng EH. A research framework to support re-engagement and continuous engagement in HIV care. Lancet HIV. 2025;12:e894-e898.
  24. Rowan SE, Patel RR, Schneider JA, et al. Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention. Lancet HIV. 2021;8:e114-e120.
  25. Baker 2023 Baker D, Collins LF, Cantos VD, et al. Early implementation of long-acting injectable cabotegravir for HIV Prevention in a safety net hospital-based primary care center in U.S. south. J Gen Intern Med. 2026;41:43-52.
  26. Johnson KA, Bui C, Graham HK, et al. The role of peer patient navigation in enhancing PrEP persistence among LGBTQ + populations and other individuals at high susceptibility to HIV transmission in the deep south state of Alabama. AIDS Behav. 2026;30:788-796.
  27. Saberi P, Mehtani NJ, Sayegh A, et al. Understanding HIV pre-exposure prophylaxis questions of U.S. health care providers: unique perspectives from the PrEPline clinical teleconsultation service. Telemed J E Health. 2023;29:376-383.
  28. National Clinician Consultation Center. PrEP : Pre-exposure prophylaxis. nccc.ucsf.edu/clinician-consultation/prep-pre-exposure-prophylaxis/. Acessed April 7, 2026.
  29. Centers for Disease Control and Prevention. Clinical guidance for PEP. cdc.gov/hivnexus/hcp/pep/index.html. Accessed April 7, 2026.